Darryl P Leong
Overview
Explore the profile of Darryl P Leong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
158
Citations
4051
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cirne F, Sedelaar M, Narayan V, Macedo A, Koo C, de Jesus J, et al.
Cardiooncology
. 2025 Mar;
11(1):28.
PMID: 40089789
Advances in the diagnosis and management of prostate cancer have significantly changed the disease landscape. While benefiting from better oncological outcomes, patients are now experiencing higher rates of non-cancer comorbidities,...
2.
Hothi H, Paolone A, Pezeshki M, Griffith L, Kennedy C, Leong D, et al.
J Am Geriatr Soc
. 2025 Mar;
PMID: 40088041
Background: Frailty is a syndrome of increased vulnerability to health stressors that is associated with adverse health outcomes. There is no universally accepted method of measuring frailty, and choosing among...
3.
Leong D, Guha A, Morgans A, Niazi T, Pinthus J
JACC CardioOncol
. 2025 Jan;
6(6):835-846.
PMID: 39801649
Cardiovascular disease is common in patients with prostate cancer and is a significant cause of death. Cardiovascular risk factors are frequent in this population and are often not addressed to...
4.
Leong D, Waliany S, Abdel-Qadir H, Atkins K, Neilan T, Lang N, et al.
JACC CardioOncol
. 2025 Jan;
6(6):815-834.
PMID: 39801647
The administration of certain cancer therapies can be associated with the development of cardiovascular toxicity or complications. This spectrum of toxicities is broad and requires nuanced approaches for prevention, identification,...
5.
Leong D, Joseph P, Dokainish H, Stork S, McMurray J, Mielniczuk L, et al.
Eur J Heart Fail
. 2024 Dec;
PMID: 39675787
Aims: The aim of this study was to describe the prognostic importance of left ventricular ejection fraction (LVEF) versus right ventricular (RV) dilatation and dysfunction in patients with heart failure...
6.
Tomkinson G, Lang J, Rubin L, McGrath R, Gower B, Boyle T, et al.
J Sport Health Sci
. 2024 Dec;
14:101014.
PMID: 39647778
Background: Muscular strength is a powerful marker of current health status and robust predictor of age-related disease and disability. Handgrip strength (HGS) using isometric dynamometry is a convenient, feasible, and...
7.
Cirne F, Moura Schmidt M, Cardoso C, Leong D, Schaan de Quadros A
Arq Bras Cardiol
. 2024 Nov;
121(11):e20240396.
PMID: 39607224
Background: The impact of performing a primary percutaneous coronary intervention (pPCI) off-hours on clinical outcomes is not well established. Objective: Compare characteristics and major adverse cardiovascular events (MACE) of pPCI...
8.
Leong D, Cirne F, Pinthus J
Cardiol Clin
. 2024 Nov;
43(1):83-91.
PMID: 39551564
Cardiovascular disease is common in patients with prostate cancer and is an important cause of death. Cardiovascular risk factors are frequent in this population and are often not addressed to...
9.
Leong D, Fradet V, Niazi T, Selvanayagam J, Sabbagh R, Higano C, et al.
JACC CardioOncol
. 2024 Oct;
6(5):761-771.
PMID: 39479325
Background: There are limited data on the physical effects of androgen deprivation therapy (ADT) for prostate cancer (PC), and on the relationships of such measures of adiposity and strength to...
10.
Leblanc K, Edwards S, Dranitsaris G, Leong D, Carrier M, Malone S, et al.
Cancers (Basel)
. 2024 Oct;
16(19).
PMID: 39409956
: Abiraterone acetate, apalutamide, darolutamide, and enzalutamide, which make up the androgen receptor axis-targeted therapies (ARATs) drug class, are commonly used in the management of prostate cancer. Many patients on...